Positive Clinical Outcomes for NOX66 at ESMO Conference
Filed with ASX · · 3 pages · English
Earlier from Noxopharm
- Important Brain Cancer Findings for NOX66 Program
- Reinstatement to Official Quotation
- Noxopharm raises $5.5 million to advance clinical program
- Suspension from Official Quotation
- Noxopharm provides update on NOX66 Clinical Trial Program
Later from Noxopharm
- Establishment of Nyrada Inc.
- Australian NOX66 - Radiotherapy Study Opens
- UNSW collaboration confirms drug designed for stroke victims
- 1st Patient treated in Lupin Study at St Vincents Hospital
- Promising Interim Clinical Data for NOX66
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm